易瑞生物(300942) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥36,475,073.45, a decrease of 39.92% compared to ¥60,707,585.25 in the same period last year[5] - The net loss attributable to shareholders was ¥7,111,078.14, representing an improvement of 74.66% from a loss of ¥28,061,115.03 in the previous year[5] - The company reported a basic earnings per share of -¥0.02, an improvement of 71.43% from -¥0.07 in the same period last year[5] - Net loss for Q1 2024 was CNY 7,273,762.66, compared to a net loss of CNY 28,085,394.84 in Q1 2023, showing an improvement in financial performance[29] - The total comprehensive income for the first quarter was -7,340,040.05 CNY, compared to -28,042,280.58 CNY in the previous year[30] Cash Flow - The net cash flow from operating activities was ¥9,412,805.78, a significant increase of 117.43% compared to -¥53,990,719.10 in the prior year[5] - Cash inflow from operating activities totaled 65,457,841.42 CNY, slightly up from 64,945,294.39 CNY year-over-year[32] - Cash outflow from operating activities decreased to 56,045,035.64 CNY from 118,936,013.49 CNY in the previous year[33] - The net cash flow from investing activities was -35,652,211.67 CNY, compared to a positive 23,962,684.77 CNY in the same quarter last year[33] - Cash flow from financing activities generated a net inflow of 46,120,022.70 CNY, reversing from a net outflow of -4,219,736.45 CNY in the previous year[33] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,396,134,877.02, reflecting a 2.93% increase from ¥1,356,339,278.93 at the end of the previous year[5] - Total liabilities increased to CNY 552,697,351.66 from CNY 507,611,047.32, reflecting a rise of 8.9%[26] - The total equity attributable to shareholders decreased to CNY 841,857,760.16 from CNY 848,993,883.06, a decline of 0.8%[26] Expenses - Total operating costs for Q1 2024 were CNY 44,390,455.72, down from CNY 94,325,423.68 year-over-year, indicating a significant reduction in expenses[28] - Research and development expenses decreased by 44.10% to ¥10,280,504.62 from ¥18,391,842.45 in the previous year, attributed to a decline in revenue[11] - The company reported a significant decrease in sales expenses by 41.45% to ¥9,732,419.01 from ¥16,621,519.54 in the previous year, reflecting a reduction in management costs[11] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 21,715, with no preferred shareholders having restored voting rights[14] - The largest shareholder, 易瑞（海南）创业投资有限公司, holds 37.67% of the shares, totaling 151,001,310 shares, with 39,420,000 shares pledged[14] - As of the end of the reporting period, 273,305,025 shares, or 68.18% of the total share capital, were released from restrictions and became tradable[19] - The company has a total of 291,651,991 restricted shares, with 218,019,593 shares released during the reporting period[17] - The company has no preferred shareholders and no changes in the number of restricted shares during the reporting period[16] Strategic Initiatives - The company signed a strategic cooperation framework agreement with the Rizhao Municipal Bureau of Agriculture and Rural Affairs on March 22, 2024, focusing on agricultural product inspection and digital transformation[22] - The company completed the election of the third board of directors and supervisory board on April 1, 2024, appointing new senior management personnel[21] Government Support - The company received government subsidies amounting to ¥1,282,962.56, which are closely related to its normal business operations[8] - The company received 7,225,626.82 CNY in tax refunds, significantly higher than 1,776,379.25 CNY in the previous year[32] Financing Activities - The company reported a significant increase in cash received from bank loans, amounting to ¥50,000,000, representing a 4091.71% increase compared to the previous period[12] - The company’s long-term borrowings increased by 47.28% to ¥147,768,840.48 from ¥100,329,007.32, primarily due to additional bank loans received[11] - The company reported a 108.82% increase in dividend, profit, or interest payments, totaling ¥1,214,913.79, primarily due to increased loan interest payments[12]